Lymphoma Diagnosis and Treatment

This study identifies a thymus-specific B-cell differentiation program linked to thymic B-cell lymphomagenesis through single-cell multiomics and spatial profiling.

This study uses intravital imaging and single-cell analysis to show that EZH2 mutations alter GC B cell motility and interactions, promoting lymphomagenesis.

The paper maps the tumor microenvironment in DLBCL using imaging mass cytometry and finds that immune-cell depleted tumors have reduced MHC-I expression and worse survival.

This study identifies POU2AF2 as a lineage-specific dependency in DLBCL, showing it coactivates POU2F2 to sustain malignant transcriptional networks and innate-like B-cell identity.

This study investigates how metabolic pathways influence cytokine production in diffuse large B-cell lymphoma, finding that glycolysis modulation affects IL-6, IL-10, and TNFα levels and that DLBCL subtypes respond differently to IL-4.

The paper uses multi-omic single-cell spatial techniques to study FL transformation, finding spatial shifts in B-cell neighborhoods and immunomodulatory interactions linked to disease progression.

This study evaluates the impact of R-CHOP chemotherapy on NK cell viability and function in DLBCL cell lines and patients, finding that treatment reduces NK cell numbers but preserves their cytotoxicity.

The paper shows that immune surveillance in germinal centers eliminates premalignant B-cells, but lymphoma-like mutations allow immune escape and progression to lymphoma.

This study identifies relapse-founding cancer persister cells in follicular lymphoma using a mouse model and shows their transcriptional program is conserved in humans, with potential therapeutic targets identified.

This study uses spatial proteomics to reveal immune evasion mechanisms in follicular lymphoma, identifying VISTA and CD14-high follicular dendritic cells as therapeutic targets.

This study identifies DDX21 as a key effector of ETS1/FLI1 in ABC-DLBCL, linking it to cell cycle, immune evasion, and snoRNA processing, with potential therapeutic implications.

The paper identifies a proteomic signature of mantle cell lymphoma (MCL) using quantitative proteomics, revealing 10 upregulated proteins that may serve as therapeutic targets.

This study identifies resistant subclones in pediatric lymphoma using scRNA-seq and scVDJ-seq, revealing progenitor-like cells and potential therapeutic targets like MSI2.

This study uses single-cell transcriptomics to analyze T cell lymphomas, identifies developmental origins, and discovers SYK and TIM3 as potential therapeutic targets.

This study shows that TET2 loss increases lymphoma penetrance and promotes survival of premalignant B cells in MYC-driven lymphoma by reducing apoptosis.

This study shows AID regulates proliferation and ABC-type transcriptional programs in DLBCL by affecting MYC/E2F pathways and IRF4/NF-κB activity.

This paper shows that CDK9 inhibitor PRT2527 kills marginal zone lymphoma cells, even those resistant to other drugs, and enhances the effects of BTK, PI3K, and BCL2 inhibitors.

The paper identifies tumor microenvironment signatures linked to morphology and prognosis in ALK-positive anaplastic large cell lymphoma using computational analysis of gene expression data.

This study shows that inhibiting MYSM1's deubiquitinase activity protects against MYC-driven B cell lymphoma through both tumor intrinsic effects and modulation of antitumor immunity.

This study shows that combining infigratinib with BTK/PI3K inhibitors or bendamustine improves efficacy in lymphoma cell models, reversing resistance and suggesting FGFR inhibition as a therapeutic strategy.

This study evaluates the preclinical efficacy of BGB-16673 and sonrotoclax in marginal zone lymphoma models, showing enhanced apoptosis when combined.

The paper characterizes ROR1 expression in B-cell lymphoma models and shows that ROR1-positive models are sensitive to a ROR1-targeting ADC.

This study identifies PLK1 inhibition as a strategy to enhance BTK blockade in MZL by overcoming resistance through transcriptomic and mechanistic analysis.

This study tests levalbuterol's anti-lymphoma effects in mice, finding significant inhibition of Mantle Cell lymphoma proliferation at higher concentrations.

The paper evaluates five PHB-targeting molecules in B cell lymphoma models, showing varied antiproliferative and cytotoxic effects across different cell lines.

This study investigates brusatol's anti-tumor effects on aggressive B-cell lymphomas, showing it inhibits growth and induces cell death, especially when combined with venetoclax.

This study identifies four molecular subtypes of Hodgkin lymphoma using multimodal data, revealing distinct clinical features and immune ecosystem dynamics.

This paper evaluates YF2, a CREBBP/p300 activator, showing it enhances cytotoxicity and immune responses in B-cell lymphoma by restoring acetylation and altering the immune microenvironment.

This study identifies MBD1 as a suppressor of BCL6 rearrangements in Burkitt lymphoma by regulating DNA methylation and genomic stability during DNA replication stress.